Equities Analysts Offer Predictions for Incyte Q4 Earnings

Incyte Co. (NASDAQ:INCY - Free Report) - Research analysts at William Blair raised their Q4 2025 earnings per share estimates for Incyte in a note issued to investors on Tuesday, April 29th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings per share of $1.25 for the quarter, up from their prior estimate of $1.16. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Incyte's current full-year earnings is $4.86 per share.

Several other research firms also recently commented on INCY. Royal Bank of Canada increased their price objective on Incyte from $64.00 to $67.00 and gave the company a "sector perform" rating in a report on Wednesday, April 30th. StockNews.com raised Incyte from a "buy" rating to a "strong-buy" rating in a report on Wednesday, April 30th. Citigroup reduced their price target on Incyte from $97.00 to $88.00 and set a "buy" rating on the stock in a research report on Tuesday, February 11th. Guggenheim cut shares of Incyte from a "buy" rating to a "neutral" rating and set a $92.00 target price for the company. in a research report on Tuesday, March 18th. Finally, Wells Fargo & Company raised their price objective on Incyte from $58.00 to $59.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Incyte presently has an average rating of "Hold" and a consensus target price of $73.53.

Incyte Stock Down 0.7 %

Shares of Incyte stock traded down $0.42 during trading hours on Friday, reaching $62.11. 1,819,461 shares of the company's stock were exchanged, compared to its average volume of 2,358,397. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $62.53 and a two-hundred day moving average of $68.89. The stock has a market cap of $12.02 billion, a P/E ratio of 230.05, a P/E/G ratio of 0.41 and a beta of 0.68. Incyte has a fifty-two week low of $52.81 and a fifty-two week high of $83.95.

Incyte (NASDAQ:INCY - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 EPS for the quarter, topping the consensus estimate of $1.01 by $0.15. Incyte had a net margin of 0.77% and a return on equity of 0.05%. The business had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $996.17 million. During the same quarter in the prior year, the company posted $0.64 earnings per share. The firm's revenue was up 19.5% on a year-over-year basis.

Insider Buying and Selling

In other Incyte news, EVP Sheila A. Denton sold 599 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total value of $41,924.01. Following the sale, the executive vice president now owns 25,848 shares in the company, valued at approximately $1,809,101.52. The trade was a 2.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Barry P. Flannelly sold 19,807 shares of the firm's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $67.69, for a total value of $1,340,735.83. Following the transaction, the executive vice president now owns 33,567 shares of the company's stock, valued at $2,272,150.23. This trade represents a 37.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,475 shares of company stock valued at $2,424,751 over the last 90 days. 17.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Incyte

Several hedge funds and other institutional investors have recently bought and sold shares of INCY. Geode Capital Management LLC lifted its stake in shares of Incyte by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 4,040,086 shares of the biopharmaceutical company's stock valued at $278,346,000 after purchasing an additional 103,910 shares during the period. AQR Capital Management LLC grew its position in shares of Incyte by 29.7% during the 4th quarter. AQR Capital Management LLC now owns 3,502,813 shares of the biopharmaceutical company's stock worth $241,519,000 after buying an additional 801,090 shares during the period. LSV Asset Management increased its stake in shares of Incyte by 18.6% in the 4th quarter. LSV Asset Management now owns 3,467,490 shares of the biopharmaceutical company's stock valued at $239,500,000 after acquiring an additional 544,080 shares in the last quarter. Bellevue Group AG lifted its position in shares of Incyte by 0.3% during the 4th quarter. Bellevue Group AG now owns 2,157,478 shares of the biopharmaceutical company's stock valued at $149,017,000 after acquiring an additional 6,927 shares during the period. Finally, Norges Bank bought a new position in Incyte during the fourth quarter worth $121,890,000. Institutional investors and hedge funds own 96.97% of the company's stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.